collection
https://read.qxmd.com/read/30731128/cryoglobulinemia-an-update-in-2019
#1
REVIEW
Anne Claire Desbois, Patrice Cacoub, David Saadoun
Cryoglobulinemia is defined as the persistent presence in serum of abnormal immunoglobulins (Igs) that precipitate at low temperatures and dissolve again upon warming. Cryoglobulins may be composed only of a monoclonal Ig (simple type I cryoglobulinemia), of a monoclonal Ig bound to the constant domain of polyclonal Ig heavy chains (mixed type II cryoglobulinemia), or only of polyclonal Igs (mixed type III cryoglobulinemia). The manifestations of type I cryoglobulinemia are often related to intravascular obstruction, whereas those seen in the mixed cryoglobulinemias often originate in true immune complex-mediated vasculitis...
November 2019: Joint, Bone, Spine: Revue du Rhumatisme
https://read.qxmd.com/read/30848549/diagnostic-accuracy-of-positron-emission-tomography-computed-tomography-of-the-head-neck-and-chest-for-giant-cell-arteritis-a-prospective-double-blind-cross-sectional-study
#2
JOURNAL ARTICLE
Anthony M Sammel, Edward Hsiao, Geoffrey Schembri, Katherine Nguyen, Janice Brewer, Leslie Schrieber, Beatrice Janssen, Peter Youssef, Clare L Fraser, Elizabeth Bailey, Dale L Bailey, Paul Roach, Rodger Laurent
OBJECTIVE: Positron emission tomography/computed tomography (PET/CT) has not been well studied as a first-line test for giant cell arteritis (GCA), due, in part, to historical limitations in visualizing the cranial arteries. The Giant Cell Arteritis and PET Scan (GAPS) study was therefore carried out to assess the accuracy of a newer generation PET/CT of the head, neck, and chest for determining a diagnosis of GCA. METHODS: In the GAPS study cohort, 64 patients with newly suspected GCA underwent time-of-flight PET/CT (1-mm slice thickness from the vertex to diaphragm) within 72 hours of starting glucocorticoids and before undergoing temporal artery biopsy (TAB)...
August 2019: Arthritis & Rheumatology
https://read.qxmd.com/read/30416807/pulmonary-vasculitis
#3
REVIEW
Ana Casal, Juan Díaz-Garel, Tara Pereiro, María E Toubes, Jorge Ricoy, Luis Valdés
Systemic vasculitides frequently affect the pulmonary vasculature. As the signs and symptoms of pulmonary vasculitis are variable and nonspecific, diagnosis and treatment represent a real challenge. Vasculitides should be given consideration, as these diseases present severe manifestations of rapidly progressing pulmonary disease. Examining other organs usually affected by vasculitides (e.g., the skin and kidneys) and determining autoantibody levels are essential to a better management of the disease. A radiological study would also contribute to establishing a diagnosis...
September 2018: Journal of Thoracic Disease
https://read.qxmd.com/read/30371823/anti-glomerular-basement-membrane-disease-an-update-on-subgroups-pathogenesis-and-therapies
#4
REVIEW
Mårten Segelmark, Thomas Hellmark
Most patients with anti-glomerular basement membrane (anti-GBM) disease present with rapidly progressive glomerulonephritis with or without pulmonary haemorrhage; however, there are several variants and vigilance is necessary to make a correct diagnosis. Such variants include overlap with anti-neutrophil cytoplasm antibodies-associated vasculitis and membranous nephropathy as well as anti-GBM occurring de novo after renal transplantation. Moreover, patients can present with isolated pulmonary haemorrhage as well as with negative tests for circulating anti-GBM...
November 1, 2019: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/29982779/prevention-of-glucocorticoid-morbidity-in-giant-cell-arteritis
#5
REVIEW
Frank Buttgereit, Eric L Matteson, Christian Dejaco, Bhaskar Dasgupta
Glucocorticoids are the mainstay of treatment for GCA. Patients often require long-term treatment that may be associated with numerous adverse effects, depending on the dose and the duration of treatment. Trends in recent decades for glucocorticoid use in GCA suggest increasing cumulative doses and longer exposures. Common adverse events (AEs) reported in glucocorticoid-treated GCA patients include osteoporosis, hypercholesterolaemia, hypertension, posterior subcapsular cataract, infections, diabetes mellitus, Cushingoid appearance, adrenal insufficiency and aseptic necrosis of bone...
February 1, 2018: Rheumatology
https://read.qxmd.com/read/29961816/immuno-monitoring-reveals-an-extended-subclinical-disease-activity-in-tocilizumab-treated-giant-cell-arteritis
#6
RANDOMIZED CONTROLLED TRIAL
Andrea D Gloor, Daniel Yerly, Sabine Adler, Stephan Reichenbach, Stefan Kuchen, Michael Seitz, Peter M Villiger
Objective: Tocilizumab is effective in inducing and maintaining remission of GCA. Despite clinical and serological control of disease, magnetic resonance angiography may show persistence of inflammatory signals of unknown significance in arterial walls. Thus, there is an unmet need for tools to detect subclinical disease activity. Methods: Immune-inflammatory markers were measured in prospectively collected sera of the first randomized, double-blind, placebo-controlled trial investigating the use of tocilizumab in GCA...
October 1, 2018: Rheumatology
https://read.qxmd.com/read/29950327/trimethoprim-sulfamethoxazole-prophylaxis-prevents-severe-life-threatening-infections-following-rituximab-in-antineutrophil-cytoplasm-antibody-associated-vasculitis
#7
JOURNAL ARTICLE
Andreas Kronbichler, Julia Kerschbaum, Seerapani Gopaluni, Joanna Tieu, Federico Alberici, Rachel Bronwen Jones, Rona M Smith, David R W Jayne
OBJECTIVE: We aimed to assess risk factors for the development of severe infection in patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV) receiving rituximab. METHODS: 192 patients with AAV were identified. Univariate and multivariate analyses were performed to identify risk factors for severe infection following rituximab. Severe infections were classified as grade ≥3 as proposed by the Common Terminology Criteria for Adverse Events V...
October 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/29734473/treatment-for-hepatitis-c-virus-associated-mixed-cryoglobulinaemia
#8
REVIEW
Nuria Montero, Alexandre Favà, Eva Rodriguez, Clara Barrios, Josep M Cruzado, Julio Pascual, Maria Jose Soler
BACKGROUND: Hepatitis C virus (HCV)-associated mixed cryoglobulinaemia is the manifestation of an inflammation of small and medium-sized vessels produced by a pathogenic IgM with rheumatoid factor activity generated by an expansion of B-cells. The immune complexes formed precipitate mainly in the skin, joints, kidneys or peripheral nerve fibres. Current therapeutic approaches are aimed at elimination of HCV infection, removal of cryoglobulins and also of the B-cell clonal expansions. The optimal treatment for it has not been established...
May 7, 2018: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/29718374/epidemiology-of-hypocomplementaemic-urticarial-vasculitis-anti-c1q-vasculitis
#9
MULTICENTER STUDY
Christopher Sjöwall, Thomas Mandl, Lillemor Skattum, Martin Olsson, Aladdin J Mohammad
OBJECTIVES: The aim was to describe the clinical characteristics and epidemiology of hypocomplementaemic urticarial vasculitis (HUV; anti-C1q vasculitis) in two geographically defined areas of Sweden. METHODS: In the health-care districts surrounding Skåne University Hospital (mean population 950 560) and Linköping University Hospital (mean population 428 503), all incident cases of HUV residing within the study areas at the onset of disease were identified during the years 2000-15...
August 1, 2018: Rheumatology
https://read.qxmd.com/read/29648680/review-what-is-the-current-evidence-for-disease-subsets-in-giant-cell-arteritis
#10
REVIEW
Kornelis S M van der Geest, Maria Sandovici, Yannick van Sleen, Jan-Stephan Sanders, Nicolaas A Bos, Wayel H Abdulahad, Coen A Stegeman, Peter Heeringa, Abraham Rutgers, Cees G M Kallenberg, Annemieke M H Boots, Elisabeth Brouwer
Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis...
September 2018: Arthritis & Rheumatology
https://read.qxmd.com/read/29625968/2018-update-of-the-eular-recommendations-for-the-management-of-beh%C3%A3-et-s-syndrome
#11
JOURNAL ARTICLE
Gulen Hatemi, Robin Christensen, Dongsik Bang, Bahram Bodaghi, Aykut Ferhat Celik, Farida Fortune, Julien Gaudric, Ahmet Gul, Ina Kötter, Pietro Leccese, Alfred Mahr, Robert Moots, Yesim Ozguler, Jutta Richter, David Saadoun, Carlo Salvarani, Francesco Scuderi, Petros P Sfikakis, Aksel Siva, Miles Stanford, Ilknur Tugal-Tutkun, Richard West, Sebahattin Yurdakul, Ignazio Olivieri, Hasan Yazici
Several new treatment modalities with different mechanisms of action have been studied in patients with Behçet's syndrome (BS). The aim of the current effort was to update the recommendations in the light of these new data under the auspices of the European League Against Rheumatism (EULAR) Standing Committee for Clinical Affairs. A task force was formed that included BS experts from different specialties including internal medicine, rheumatology, ophthalmology, dermatology, neurology, gastroenterology, oral health medicine and vascular surgery, along with a methodologist, a health professional, two patients and two fellows in charge of the systematic literature search...
June 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/29535124/efficacy-and-safety-of-biologics-in-relapsing-polychondritis-a-french-national-multicentre-study
#12
MULTICENTER STUDY
Guillaume Moulis, Grégory Pugnet, Nathalie Costedoat-Chalumeau, Alexis Mathian, Gaëlle Leroux, Jonathan Boutémy, Olivier Espitia, Laurence Bouillet, Sabine Berthier, Jean-Baptiste Gaultier, Pierre-Yves Jeandel, Amadou Konaté, Arsène Mékinian, Elisabeth Solau-Gervais, Benjamin Terrier, Daniel Wendling, Fanny Andry, Camille Garnier, Pascal Cathébras, Laurent Arnaud, Aurore Palmaro, Patrice Cacoub, Zahir Amoura, Jean-Charles Piette, Philippe Arlet, Maryse Lapeyre-Mestre, Laurent Sailler
OBJECTIVES: To assess the efficacy and the safety of biologics in a cohort of patients with relapsing polychondritis (RP). METHODS: We conducted a French multicentre retrospective cohort study including patients treated with biologics for RP. Efficacy outcomes were clinical response (partial or complete) and complete response during the first 6 months of exposure, plus daily corticosteroid dose at 6 months. Other outcomes were adverse drug reactions (ADRs), persistence of biologics and factors associated with a response...
August 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/29526627/cryoglobulins-an-update-on-detection-mechanisms-and-clinical-contribution
#13
REVIEW
Marie-Nathalie Kolopp-Sarda, Pierre Miossec
Cryoglobulins are immunoglobulins precipitating in cold condition. They are classified in 3 types according to the Brouet classification and may lead to vasculitis of small and medium size vessels. Vasculitis is related to vessel obstruction by monoclonal cryoglobulin aggregates in type I cryoglobulins and immune complex deposition in type II and III mixed cryoglobulins. This phenomenon is favored by low temperature, especially in skin, joints, and peripheral nerves, or increased cryoglobulin concentration in kidneys...
May 2018: Autoimmunity Reviews
https://read.qxmd.com/read/29465365/polyarteritis-nodosa-revisited-a-review-of-historical-approaches-subphenotypes-and-a-research-agenda
#14
REVIEW
Omer Karadag, David J Jayne
Polyarteritis nodosa (PAN) is a rare form of primary systemic vasculitis with heterogeneous presentations, treatments and disease course. Historical approaches to classification and diagnostic terminology are reviewed. Since differentiation of PAN from microscopic polyangiitis (MPA) and other ANCA vasculitides by the Chapel Hill conference statements, and with hepatitis associated PAN defined as a secondary vasculitis, the phenotyping and subclassification of PAN has received little attention. Monogenic disorders similar to PAN have been described (familial Mediterranean fever, Adenosine Deaminase-2 deficiency), and cutaneous PAN and single organ vasculitis, discussed...
March 2018: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/29453944/clinical-features-of-extrapulmonary-sarcoidosis-without-lung-involvement
#15
MULTICENTER STUDY
Walter Ennis James, Efstratios Koutroumpakis, Biplab Saha, Alireza Nathani, Leahruth Saavedra, Recai M Yucel, Marc A Judson
BACKGROUND: Compared with pulmonary sarcoidosis, sarcoidosis without lung involvement may involve other immunopathologic mechanisms and be associated with other demographic and clinical features. METHODS: This was a retrospective analysis of clinical data collected in real time on 1,686 patients with biopsy-proven sarcoidosis from two large university sarcoidosis outpatient clinics in the United States. We compared differences in demographics characteristics and clinical presentation between pulmonary and nonpulmonary sarcoidosis (NPS)...
August 2018: Chest
https://read.qxmd.com/read/28905861/giant-cell-arteritis-and-polymyalgia-rheumatica-current-challenges-and-opportunities
#16
REVIEW
Christian Dejaco, Elisabeth Brouwer, Justin C Mason, Frank Buttgereit, Eric L Matteson, Bhaskar Dasgupta
The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions...
October 2017: Nature Reviews. Rheumatology
https://read.qxmd.com/read/29296024/beh%C3%A3-et-syndrome-a-contemporary-view
#17
REVIEW
Hasan Yazici, Emire Seyahi, Gulen Hatemi, Yusuf Yazici
The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn's disease suggest multiple pathological pathways are involved in Behçet syndrome. These features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 to be the important genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bone fide disease, especially in non-endemic regions, suggests other factors must also be operative in Behçet syndrome...
February 2018: Nature Reviews. Rheumatology
https://read.qxmd.com/read/29148423/non-invasive-vascular-biomarkers-in-patients-with-beh%C3%A3-et-s-disease-review-of-the-data-and-future-perspectives
#18
REVIEW
Athanase D Protogerou, Efthimia G Nasothimiou, Petros P Sfikakis, Athanasios G Tzioufas
Vascular inflammation in small to large veins and arteries contributes substantially to mortality above that of the general population in Behçet's disease. Recent data verified also the presence of accelerated classical subclinical arterial damage (atheromatosis, arteriosclerosis, arterial hypertrophy) even in patients free of overt vascular complications, and may be complementary to that of vasculitis. Early detection of such vascular damage might provide helpful pathophysiological insight and potentially even guide treatment management...
November 2017: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/28973844/brief-report-rituximab-for-the-treatment-of-adult-onset-iga-vasculitis-henoch-sch%C3%A3-nlein
#19
MULTICENTER STUDY
Federica Maritati, Roberta Fenoglio, Evangeline Pillebout, Giacomo Emmi, Maria L Urban, Rossana Rocco, Maria Nicastro, Monia Incerti, Matteo Goldoni, Giorgio Trivioli, Elena Silvestri, Aladdin J Mohammad, David Jayne, Per Eriksson, Mårten Segelmark, Pavel Novikov, Helen Harris, Dario Roccatello, Augusto Vaglio
OBJECTIVE: Adult-onset IgA vasculitis (Henoch-Schönlein) (IgAV) is a rare systemic vasculitis characterized by IgA1-dominant deposits. The treatment of adult-onset IgAV is controversial and is based on the combination of glucocorticoids and immunosuppressive agents, but many patients have refractory or relapsing disease despite treatment. Rituximab (RTX) is a B cell-depleting antibody of proven efficacy in antineutrophil cytoplasmic antibody-associated vasculitis. We undertook this study to test the efficacy and safety of RTX in a multicenter cohort of patients with adult-onset IgAV...
January 2018: Arthritis & Rheumatology
https://read.qxmd.com/read/29136340/nomenclature-of-cutaneous-vasculitis-dermatologic-addendum-to-the-2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-vasculitides
#20
REVIEW
Cord H Sunderkötter, Bernhard Zelger, Ko-Ron Chen, Luis Requena, Warren Piette, J Andrew Carlson, Jan Dutz, Peter Lamprecht, Alfred Mahr, Elisabeth Aberer, Victoria P Werth, David A Wetter, Seiji Kawana, Raashid Luqmani, Camille Frances, Joseph Jorizzo, J Richard Watts, Dieter Metze, Marzia Caproni, Erkan Alpsoy, Jeffrey P Callen, David Fiorentino, Peter A Merkel, Ronald J Falk, J Charles Jennette
OBJECTIVE: To prepare a dermatologic addendum to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012) to address vasculitides affecting the skin (D-CHCC). The goal was to standardize the names and definitions for cutaneous vasculitis. METHODS: A nominal group technique with a facilitator was used to reach consensus on the D-CHCC nomenclature, using multiple face-to-face meetings, e-mail discussions, and teleconferences...
February 2018: Arthritis & Rheumatology
label_collection
label_collection
6417
1
2
2017-11-21 14:23:32
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.